leadf
logo-loader
viewVerona Pharma

Verona Pharma splutters as lead COPD drug disappoints in Phase II study

Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped

coughing
COPD covers a number of conditions that cause difficulty breathing

Verona Pharma PLC (LON:VRP) saw more than a fifth wiped from its value after its lead drug, a potential treatment for chronic obstructive pulmonary disease (COPD), failed to meet the primary endpoint of a mid-stage clinical trial.

The three-day Phase II study saw COPD patients given either 1.5mg or 6.0mg of ensifentrine in combination with Stiolto Respimat – a commonly used maintenance treatment for COPD patients.

Boss still optimistic

Results from the trial showed that ensifentrine did not improve breathing by a “statistically significant” amount, although it was better than a placebo

“While we are disappointed that this exploratory Phase 2 study did not achieve statistical significance for its primary endpoint, these data give us clarity on the design, including dose and background therapy, for future long-term studies,” said chief executive Jan-Anders Karlsson.

“Having demonstrated in previous studies the potential of ensifentrine to deliver benefits to patients on no or single bronchodilator therapy, we believe that this short study continues to support our view that ensifentrine may also be of benefit to more severe COPD patients on dual and triple therapy, for whom there are few other treatment options.”

The market didn’t share the same sense of optimism, with the stock slipping 21% to 82.2p on Monday morning.

Quick facts: Verona Pharma

Price: 65.11 GBX

AIM:VRP
Market: AIM
Market Cap: £269.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Integumen PLC to seek fast-track approval for its new coronavirus breath test

Integumen PLC's (LON:SKIN) Gerry Brandon speaks to Proactive's Andrew Scott after unveiling a new personalised coronavirus breath test, Microtox BT, and a complimentary digital health pass platform which he says has the potential to enable instant real-time testing for the virus. Brandon says...

1 hour, 57 minutes ago

2 min read